A review in Diabetes Therapy concluded that GLP-1 receptor agonists—including liraglutide and semaglutide—along with the dual-acting drug tirzepatide, show promise in stopping type 2 diabetes from progressing in people with prediabetes. The coverage frames the evidence as supportive of interventions that push prediabetes toward regression or stabilization rather than relying only on lifestyle changes. It is positioned as a “sweeping review,” emphasizing synthesis across available clinical findings for the class. For biotech companies with cardiometabolic portfolios, the review reinforces demand for prediabetes and prevention indications, a category increasingly competitive due to GLP-1-driven commercial scale. Regulatory strategy and reimbursement will likely depend on how trials define meaningful endpoints beyond glycemic measures, such as durability of reversion and safety profiles in broader primary-care populations.